Core Viewpoint - PVH Corp. has lowered its FY25 guidance and second-quarter adjusted EPS guidance, leading to a decline in share price despite beating quarterly earnings and revenue estimates [1][2]. Financial Performance - PVH reported quarterly earnings of $2.30 per share, exceeding the analyst consensus estimate of $2.25, and quarterly revenue of $1.98 billion, surpassing the Street estimate of $1.93 billion [1]. - The company has revised its fiscal 2026 adjusted EPS guidance from a range of $12.40 to $12.75 down to $10.75 to $11, compared to the analyst estimate of $12.52 [2]. Analyst Insights - Telsey Advisory Group analyst Dana Telsey maintained an Outperform rating with a $90 price target, noting that while PVH posted a first-quarter beat, its operating margin fell short due to gross margin pressures [2][3]. - Needham analyst Tom Nikic reiterated a Buy rating with a $115 price target, suggesting that the guidance cut may exert selling pressure but believes the downward revision was largely priced in [4]. - Evercore ISI Group analyst Michael Binetti reaffirmed an Outperform rating while trimming the price forecast from $105 to $95 [6]. Market Reaction - PVH shares are down 16.71% at $67.35 following the announcement [6]. - Several analysts have adjusted their price targets and ratings post-results, with Wells Fargo cutting its forecast from $100 to $80 and BMO Capital lowering its forecast from $93 to $84 [5].

Core Insights - Newmont Corporation (NEM) achieved a record first-quarter free cash flow of $1.2 billion, a significant improvement from a negative $74 million in the same period last year, driven by enhanced operational efficiency and a strong Tier 1 portfolio [1][7] - Despite the strong first-quarter performance, sustainability concerns exist for the second quarter due to non-core asset divestitures, increased tax payments, and higher capital expenditures [2][3][7] - The anticipated decline in free cash flow is attributed to long-term growth initiatives rather than deteriorating fundamentals, supported by a solid balance sheet [3][7] Peer Comparisons - Barrick Mining Corporation reported a free cash flow of $375 million for the first quarter, reflecting a nearly 12-fold year-over-year increase due to higher operating cash flows from increased gold and copper prices [4] - Agnico Eagle Mines Limited generated first-quarter free cash flows of $594 million, up approximately 50% year over year, supported by strong gold prices and operational results [5] Market Performance - Newmont's shares have increased by 48.5% year to date, compared to a 53.9% rise in the Zacks Mining – Gold industry, largely driven by the rally in gold prices [6] - The Zacks Consensus Estimate for NEM's earnings in 2025 and 2026 implies year-over-year increases of 20.1% and 11.7%, respectively, with EPS estimates trending higher over the past 60 days [8] - NEM is currently trading at a forward 12-month earnings multiple of 12.59, approximately 10% below the industry average of 13.97 [9]

Group 1 - Moretus Research provides high-quality equity research focused on U.S. public markets, aiming to deliver clarity, conviction, and alpha for serious investors [1] - The research framework identifies companies with durable business models, mispriced cash flow potential, and intelligent capital allocation, emphasizing a structured and repeatable approach [1] - Valuation methods are based on sector-relevant multiples tailored to each company's business model and capital structure, prioritizing comparability, simplicity, and relevance [1] Group 2 - Research coverage focuses on underappreciated companies experiencing structural changes or temporary dislocations, where disciplined analysis can yield asymmetric returns [1] - Moretus Research aims to elevate the standard for independent investment research by providing professional-grade insights and actionable valuation [1]

Group 1 - The article emphasizes the importance of investing in companies that demonstrate growth in revenue, earnings, and free cash flow [1] - It highlights the preference for companies with excellent growth prospects and favorable valuations [1] - The focus is on steadily growing companies with high free cash flow margins, dividend stocks, and those with generous share repurchase programs [1]

The leading membership warehouse retailer reported impressive numbers in its most recent earnings report, highlighting the company's robust customer base at a time when consumers are pulling back at many other stores. The stock's long-term performance is legendary. Costco's shares have risen by over 600% in the past decade alone. The company was a favorite of the late Charlie Munger, who, alongside Warren Buffett, helped run Berkshire Hathaway for decades. Costco Wholesale's share price has risen 600% over ...

Entel SA (ENTEL.SN) Trimming Estimates Post-1Q25 27 May 2025 | 5:20PM BRT | ENTEL.SN | | --- | | 12m Price Target: Ch$3,450 | | Price: Ch$2,791 | | Upside: 23.6% | We incorporate 1Q25 earnings as well as updated macro/FX assumptions, lowering estimates particularly in Chile, given i) somewhat more-conservative ARPU assumptions amid continued competitive pressure from AMX and WOM in mobile, though we already assumed some increased competition this year; ii) weaker-than-expected fiber trends, with management ...

Investment Rating - The investment rating for Meiji Holdings is Neutral, with a 12-month target price revised to ¥3,400 from ¥3,500, reflecting a slight decrease in operating profit estimates [1][18][22]. Core Insights - The report indicates that operating profits for FY3/25 are expected to miss guidance, primarily due to anticipated shortfalls in sales across domestic milk, the dairy overseas business, and the vaccines/animal health business [1][17]. - The company has a significant market share in Japan for dairy products, chocolate, and protein products, but its growth prospects are considered to be adequately reflected in the current share price [22]. - The report highlights the importance of monitoring input costs, price hikes, and sales recovery in the food segment, as well as growth in the pharmaceuticals segment, particularly in vaccines and overseas business expansion [19][22]. Financial Estimates - FY3/26 operating profit estimates have been adjusted by -0.1% for the overall company, with specific adjustments of +¥0.7 billion for the food segment and +¥0.2 billion for the pharmaceuticals segment, while adjustments account for a decrease of -¥1.0 billion [1][17]. - Sales estimates for FY3/26 are projected at ¥1,192.2 billion, reflecting a year-on-year growth of 3.3% [3][20]. - The net profit for FY3/26 is estimated at ¥53.9 billion, with an EPS of ¥202.1 [3][20]. Segment Performance - The food segment's operating profit is expected to be ¥70.7 billion for FY3/26, while the pharmaceuticals segment is projected at ¥25.7 billion [20]. - Key areas of focus for the food segment include dairy, chocolate, and nutrition, with specific sales estimates for dairy at ¥273.5 billion and chocolate at ¥177.2 billion for FY3/26 [20]. - The pharmaceuticals segment is anticipated to see growth driven by vaccines and the expansion of the overseas CMO/CDMO business, despite challenges from drug price revisions [19][22].

Core Viewpoint - Dollar Tree, Inc. is expected to report a decline in both revenue and earnings for the first quarter of fiscal 2025, with significant pressures from reduced consumer spending and inflationary challenges [1][5][7]. Financial Performance - The Zacks Consensus Estimate for revenues is $4.5 billion, reflecting a 40.5% decrease from the same quarter last year [1]. - The consensus estimate for earnings is $1.20 per share, indicating a 16.1% decline year-over-year [1]. - The company has a trailing four-quarter negative earnings surprise of 8.4% on average, with the last quarter's earnings missing the estimate by 3.2% [4]. Market Trends - Continued soft demand for discretionary items is anticipated due to reduced spending among low-income consumers [5]. - Inflationary pressures and increased interest rates are contributing to the company's challenges [5]. - Adverse foreign currency translations are also negatively impacting performance [5]. Operational Adjustments - The company is diversifying its supplier base and exploring alternative manufacturing locations to mitigate risks from additional tariffs [6]. - Adjustments to sourcing strategies may lead to transitional inefficiencies and increased short-term costs, affecting first-quarter results [6]. Cost Structure - Higher selling, general and administrative (SG&A) expenses are expected to negatively impact the top and bottom lines due to elevated operating costs [7]. - Earnings are projected to be negatively impacted by 30-35 cents per share due to shared service costs related to the Family Dollar sale [9]. Strategic Initiatives - Dollar Tree is making progress on restructuring and expansion initiatives, including steady store openings and improvements in distribution centers [10]. - Management predicts comparable store sales growth of 3-5%, with a model forecasting a 4.7% year-over-year increase for the Dollar Tree banner [11]. Valuation Insights - Dollar Tree shares are trading at a forward 12-month price-to-earnings ratio of 16.47X, below the five-year median of 17.86X and the industry average of 33.28X, indicating attractive valuation [13]. - The stock has gained 230.7% in the past three months, contrasting with a 1.3% decline in the industry [16].

Core Viewpoint - Elevance Health, Inc. is trading at a discount with a forward 12-month P/E ratio of 10.35X, below its five-year median of 13.46X and the industry average of 13.86X, indicating attractive valuation compared to peers [1][2] Group 1: Growth Drivers - Elevance is positioned for sustained growth through strategic initiatives in its commercial and government segments, with commercial memberships growing 4.6% and 1% year-over-year in 2024, and a notable 14.2% increase in its Individual Commercial business in Q1 2025 [4][5] - The company has streamlined its government business by exiting underperforming markets, enhancing efficiency and potential for growth in Medicare Advantage in underpenetrated states [5] - Elevance's Return on Invested Capital stands at 9.94%, significantly above the industry average of 5.79%, showcasing superior capital deployment capabilities [6] Group 2: Shareholder Returns - The company is committed to returning capital to shareholders, having repurchased $880 million worth of shares in Q1 2025, with $8.4 billion remaining under its buyback authorization, and a dividend yield of 1.82%, exceeding the industry average of 1.40% [7] Group 3: Market Performance - Despite broader market challenges, Elevance shares have gained 1.9% year-to-date, outperforming both the industry and the S&P 500, while peers UnitedHealth and Humana have experienced declines [8] Group 4: Financial Estimates - The Zacks Consensus Estimate for Elevance's EPS indicates a 4.2% increase for 2025 and a 13.8% increase for 2026, with revenue estimates suggesting an 11.2% increase for 2025 and a 7.1% increase for 2026 [11] Group 5: Challenges and Risks - Elevance faces challenges including a decline in Medicaid and Medicare Supplement membership, which could lead to overall membership losses and reduced revenues [12] - Rising medical costs are a significant concern, with the benefit expense ratio increasing from 87% in 2023 to an estimated 88.7% in 2025, indicating pressure on earnings [13] - Regulatory uncertainties, particularly related to the Pharmacy Benefit Management industry, pose additional risks for Elevance [14]

Group 1 - Moretus Research provides high-quality equity research focused on U.S. public markets, aiming to deliver clarity, conviction, and alpha for serious investors [1] - The research framework identifies companies with durable business models, mispriced cash flow potential, and intelligent capital allocation, emphasizing a structured and repeatable approach [1] - Valuation methods are based on sector-relevant multiples tailored to each company's business model and capital structure, prioritizing comparability, simplicity, and relevance [1] Group 2 - Research coverage focuses on underappreciated companies experiencing structural changes or temporary dislocations, where disciplined analysis can yield asymmetric returns [1] - Moretus Research aims to elevate the standard for independent investment research by providing professional-grade insights and actionable valuation [1]